Neurocrine Biosciences (NBIX) Price Target Increased to $100.00 by Analysts at JPMorgan Chase & Co.

Neurocrine Biosciences (NASDAQ:NBIX) had its target price lifted by analysts at JPMorgan Chase & Co. from $79.00 to $100.00 in a research report issued to clients and investors on Wednesday. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 19.49% from the company’s current price.

NBIX has been the subject of a number of other research reports. Robert W. Baird reaffirmed a “buy” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Needham & Company LLC increased their price objective on Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Piper Jaffray Companies reiterated a “buy” rating and issued a $76.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. Oppenheimer set a $95.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Monday, January 15th. Finally, Deutsche Bank reiterated a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Neurocrine Biosciences presently has an average rating of “Buy” and a consensus target price of $88.33.

Shares of Neurocrine Biosciences (NBIX) traded up $1.52 during mid-day trading on Wednesday, reaching $83.69. The company had a trading volume of 780,300 shares, compared to its average volume of 1,024,196. Neurocrine Biosciences has a 12 month low of $39.21 and a 12 month high of $91.82. The stock has a market capitalization of $7,271.47, a price-to-earnings ratio of -39.37, a price-to-earnings-growth ratio of 6.41 and a beta of 0.26. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The company had revenue of $94.52 million during the quarter, compared to the consensus estimate of $94.00 million. During the same period last year, the firm earned ($0.51) earnings per share. research analysts predict that Neurocrine Biosciences will post -1.48 EPS for the current year.

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $72.92, for a total value of $729,200.00. Following the transaction, the director now directly owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin Charles Gorman sold 105,983 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $80.25, for a total value of $8,505,135.75. Following the completion of the transaction, the chief executive officer now directly owns 339,482 shares in the company, valued at $27,243,430.50. The disclosure for this sale can be found here. Insiders sold a total of 337,950 shares of company stock valued at $26,613,876 over the last quarter. 4.80% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in NBIX. The Manufacturers Life Insurance Company boosted its position in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the last quarter. Crow Point Partners LLC purchased a new position in Neurocrine Biosciences in the fourth quarter worth about $145,000. American International Group Inc. purchased a new position in Neurocrine Biosciences in the fourth quarter worth about $161,000. M&T Bank Corp purchased a new position in Neurocrine Biosciences in the fourth quarter worth about $202,000. Finally, Mission Wealth Management LP purchased a new position in Neurocrine Biosciences in the fourth quarter worth about $204,000.

ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences (NBIX) Price Target Increased to $100.00 by Analysts at JPMorgan Chase & Co.” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/14/neurocrine-biosciences-nbix-price-target-increased-to-100-00-by-analysts-at-jpmorgan-chase-co.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply